Karl Kieburtz, M.D., M.P.H.
To arrange an interview, please call Public Relations, 585-275-3676. To reach a source after hours, please call 585-275-2222 and have the P.R. person on call paged.
Neurologist Karl Kieburtz has helped establish networks of neurologists that serve as the hub for many of the world’s largest studies of new treatments for neurological conditions. The groups serve as models of collaboration, bringing together hundreds of investigators from dozens of sites to work together in the search for new treatments for neurodegenerative disorders like Parkinson’s and Huntington’s diseases.
More broadly, Kieburtz is an expert on the design and implementation of large-scale, multi-site clinical studies. He has served as chair of the FDA Peripheral and Central Nervous System Drugs Advisory Committee, and he is an active consultant to both the FDA and the National Institutes of Health.
Kieburtz was one of the founders and a former chair of the Parkinson Study Group, a group that unites more than 350 researchers across three continents whose studies have led to the approval of several new medications to treat the disease. He is the principal investigator of a series of studies sponsored by NIH to search for neuroprotective agents to help protect brain cells and slow or prevent the damage caused by Parkinson’s disease. The group is currently monitoring the progression of the disease in more than 1,700 patients who are taking the nutritional supplement creatine.
Kieburtz is also a member of the executive committee of the worldwide Huntington Study Group, whose work led to the approval of the first drug, tetrabenazine, ever approved in the United States to treat the disease. The team is currently doing a large study to explore the effects of treatment with the supplement coenzyme Q10 or CQ10; Kieburtz has previously shown that the substance holds promise for slowing the decline in patients with Huntington’s disease.